Olmesartán/Amlodipino/Hidroclorotiazida Teva

Olmesartan medoxil, the active ingredient in Olmesartán/Amlodipino/Hidroclorotiazida Teva, is an angiotensin II receptor blocker presented as a combination tablet for oral use. It treats hypertension, often in adults who require multiple mechanisms to control blood pressure. GNH USA supplies Olmesartán/Amlodipino/Hidroclorotiazida Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

GNH USA supplies Olmesartán/Amlodipino/Hidroclorotiazida Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan medoxil/amlodipine/hydrochlorothiazide is used in the management of hypertension, acting on several physiological pathways that regulate blood pressure. - Essential hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Hypertension with edema: provides vasodilation and diuresis to alleviate fluid retention. - Hypertension in patients with diabetes: helps protect renal function while controlling blood pressure. - Resistant hypertension: adds an ARB, calcium‑channel blocker and thiazide diuretic for synergistic effect. - Hypertension post‑myocardial infarction: contributes to secondary prevention by maintaining target blood pressure levels.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Peripheral edema: swelling of ankles or feet due to vasodilatory effect. - Dizziness or light‑headedness: especially after the first doses. - Fatigue: general feeling of tiredness. - Cough: occasional dry cough. - Increased urination: related to the diuretic component.

Serious or Rare Side Effects: - Angio‑edema: rapid swelling of lips, tongue or throat requiring emergency care. - Severe hypotension: marked drop in blood pressure causing fainting. - Electrolyte disturbances: significant changes in potassium or sodium levels. - Acute kidney injury: sudden decline in renal function. - Liver function abnormalities: elevated transaminases. - Blood dyscrasias: rare blood cell count abnormalities.

Before initiating therapy, assess renal function, electrolytes and blood pressure response. - Monitor blood pressure: ensure target levels are achieved without excessive drop. - Check renal function: adjust dosing if creatinine clearance is reduced. - Review electrolyte status: watch for potassium or sodium imbalances. - Evaluate for heart failure: monitor for signs of fluid overload or worsening edema. - Avoid concurrent use with other potent vasodilators: may increase hypotension risk. - Store at ambient temperature: keep below 25°C, retain in original packaging and protect from moisture.

Olmesartan/amlodipine/hydrochlorothiazide may interact with several drug classes.

Major Interactions (Avoid): - Dual renin‑angiotensin system blockade: concurrent ACE inhibitors or aliskiren can increase risk of renal impairment and hyperkalaemia. - Potassium‑sparing diuretics: may cause dangerous hyperkalaemia. - Strong CYP3A4 inhibitors: can raise amlodipine levels, increasing hypotension risk.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may blunt antihypertensive effect and affect renal function. - Lithium: may increase lithium levels, risking toxicity. - Antidiabetic agents: may enhance glucose‑lowering effect, requiring dose adjustment. - Alcohol: additive hypotensive effect, especially after initial dosing. - Digoxin: increased risk of digoxin toxicity due to electrolyte shifts.